

## EDITORIAL

## Osr1 Is a Critical Regulator of Macrophage Polarization in NASH Progression

Nonalcoholic steatohepatitis (NASH) is a chronic liver disease, an aggressive form of nonalcoholic fatty liver disease (NAFLD) by the mixture of liver inflammation, steatosis, and fibrosis, that is becoming a leading cause of liver-related morbidity and mortality worldwide.<sup>1</sup> To reach the stage of NASH from simple steatosis, the immune cell-mediated inflammatory process is considered as a major step.<sup>1</sup> Since their discovery in 1876, Kupffer cells (KCs) have been identified as liver resident macrophages to preserve tissue homeostasis.<sup>2</sup> KCs are originated from yolk sac-derived progenitor cells, while monocyte-derived macrophages are also recruited into the liver from peripheral blood. It remains to be determined which group of macrophages is a major contributing cell type in NASH progression and what the underlying molecular mechanism is.

Macrophages are functionally dynamic with levels of plasticity. Under induction of different microenvironmental cues, macrophages can be polarized into classically activated macrophages (M1) or alternatively activated macrophages (M2). The M1 and M2 macrophages may have opposing roles in many pathophysiological processes, such as tumorigenesis, tissue repair, and metabolism in the context of diseases.<sup>3</sup> Despite extensive analyses of liver macrophages in steatosis and NASH for many years, it remains unclear if macrophage polarization happens due to replacing monocyte-derived macrophage for KC loss or if KCs can be easily polarized. Furthermore, it is important to determine which molecules are the intrinsic switching factor(s) to polarize macrophages in promoting NASH progression.

In this issue of *Cellular and Molecular Gastroenterology and Hepatology*, Liu et al<sup>4</sup> investigated cell type-specific odd skipped-related 1 (*Osr1*) effects in 4 different NASH mouse models. *Osr1*, a member of the OSR family, is a C2H2-containing zinc finger transcription factor that is involved in embryonic development and cancer cell proliferation.<sup>5,6</sup> Xie's group reported previously that the whole-body *Osr1* gene deletion promotes NASH progression in mice,<sup>7,8</sup> but it is unclear which type of cells was responsible for the NASH-promoting effect. This study showed that *Osr1* was highly expressed in myeloid cells compared with other cells in human livers with NASH and in mouse NASH models. Further, the authors detected high levels of *Osr1* expression in monocyte-derived macrophages (F4/80<sup>+</sup> Clec4f<sup>-</sup>), which exhibited M2-like phenotypes, in methionine choline-deficient and high-fat diet models.

To decipher a cell type-specific role of *Osr1*, the authors generated mutant mouse lines with *Osr1* deleted in hepatocytes (*Osr1*<sup>F/F</sup>:Alb-Cre) or in myeloid cells (*Osr1*<sup>F/F</sup>:LysM-Cre) and treated the mice with methionine choline-deficient

and high-fat diets. Interestingly, *Osr1* loss in myeloid cells, but not hepatocytes, promoted steatosis and hepatic inflammation for aggressive NASH development. *Osr1*-deficient macrophages were skewed to M1 macrophages secreting proinflammatory cytokines (tumor necrosis factor  $\alpha$  and interleukin-1 $\beta$ ). To understand if *Osr1* removal from myeloid cells facilitated the reprogramming of M1 macrophages upon stimuli, exposure to lipopolysaccharide and interleukin-4 was applied to bone marrow-derived macrophages isolated from control (*Osr1*<sup>F/F</sup>) and *Osr1* <sup>$\Delta$ Mac</sup> mice. Interestingly, *Osr1*-deficient macrophages were more responsive to lipopolysaccharide treatment; featured elevated activation of p38, JNK, and nuclear factor  $\kappa$ B pathways; and were accompanied by an augmented expression of proinflammatory cytokines. However, bone marrow-derived macrophages isolated from *Osr1* <sup>$\Delta$ Mac</sup> livers were poorly responsive to interleukin-4 exposure, suggesting that *Osr1* deficiency strongly skewed M1-like macrophages. Thus, *Osr1* is a critical transcription factor in the regulation of alternative macrophage polarization.

Given *Osr1* deletion in myeloid cells is favored toward the M1 phenotype to promote NASH progression, the authors investigated the downstream targets of *Osr1* in reprogramming the macrophage phenotypes. By performing unsupervised transcriptomic analysis, the researchers identified PPAR $\gamma$  and Myc as potential candidates. Further investigation confirmed PPAR $\gamma$  and Myc as direct targets of *Osr1* by chromatin immunoprecipitation polymerase chain reaction and luciferase reporter assay in regulation of macrophage polarization. Rescuing PPAR $\gamma$  function by treatment of rosiglitazone, a PPAR $\gamma$  agonist, or exogenous expression of *Osr1*, delivered by an adeno-associated virus system, led to liver inflammation resolution and restoration of the M2-like phenotypes. These data suggest that PPAR $\gamma$  is a downstream target of *Osr1* in mediating macrophage polarization. Moreover, rosiglitazone treatment restored the oxygen consumption rate, featured by a decreased ratio of glycolysis vs OXPHOS in *Osr1*-deficient macrophages. Indeed, it rescued *Osr1* expression to alleviate the NAFLD/NASH symptoms and liver inflammation. *Osr1*-expressing macrophages exhibited M2-like phenotypes (F4/80<sup>+</sup>Clec4f<sup>-</sup>), which are not KCs. Indeed, the putative role of KCs was not explored in this study. The cellular properties of *Osr1*-deficient macrophages and the underlying molecular mechanisms in driving NASH development are not fully understood yet. Nonetheless, this study identified *Osr1* as a transcription factor that plays a critical role in the regulation of macrophage polarization. A promising therapeutic approach by targeting *Osr1*-mediated macrophages or using

117 rosiglitazone for activation of the *Osr1*-PPAR $\gamma$  axis could be  
118 beneficial for patients suffering from NAFLD/NASH.

119  
120 *JIN LEE, PhD*

121 *Q8 GEN-SHENG FENG, BSc, MSc, PhD*  
122 Department of Pathology  
123 University of California San Diego  
124 La Jolla, California  
125 Department of Molecular Biology  
126 University of California San Diego  
127 La Jolla, California  
128 Moores Cancer Center  
129 University of California San Diego  
130 La Jolla, California

## 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175

- 131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175
1. Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. *Nat Rev Immunol* 2022; 22:429–443.
  2. Dixon LJ, Barnes M, Tang H, et al. Kupffer cells in the liver. *Compr Physiol* 2013;3:785–797.
  3. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. *Nat Rev Immunol* 2011;11:750–761.
  4. Liu L, Zhou Y, Liu Z, et al. *Osr1* regulates macrophage-mediated liver inflammation in non-alcoholic fatty liver disease progression. *Cell Mol Gastroenterol Hepatol* 2023;●●:●●●–●●●.

5. Han L, Xu J, Grigg E, et al. *Osr1* functions downstream of Hedgehog pathway to regulate foregut development. *Dev Biol* 2017;427:72–83.
6. Vallecillo-Garcia P, Orgeur M, Vom Hofe-Schneider S, et al. Odd skipped-related 1 identifies a population of embryonic fibro-adipogenic progenitors regulating myogenesis during limb development. *Nat Commun* 2017; 8:1218.
7. Lynch EC, Liu Z, Liu L, et al. Disrupting *Osr1* expression promoted hepatic steatosis and inflammation induced by high-fat diet in the mouse model. *PLoS One* 2022;17: e0268344.
8. Zhou Y, Liu Z, Lynch EC, et al. *Osr1* regulates hepatic inflammation and cell survival in the progression of non-alcoholic fatty liver disease. *Lab Invest* 2020; 101:477–489.

### Correspondence

Address correspondence to Gen-Sheng Feng, BSc, MSc, PhD, Department of Pathology, University of California San Diego, 9500 Gilman Drive, mail code 0864, La Jolla, California 92093-0864. e-mail: [gfeng@ucsd.edu](mailto:gfeng@ucsd.edu).

### Conflicts of Interest

The authors disclose no conflicts.

© 2023 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

2352-345X

<https://doi.org/10.1016/j.jcmgh.2023.01.009>